Revascularisation for Ischaemic Ventricular Dysfunction

A multicentre prospective randomised open controlled trial.

Aim: To evaluate the efficacy and safety of percutaneous coronary intervention compared to optimal medical therapy alone for ischaemic left ventricular dysfunction.


Primary Endpoint: All-cause death or hospitalisation due to heart failure

Secondary Endpoints:

  • Quality of life score:
    • Kansas City Cardiomyopathy Questionnaire (KCCQ)
    • EuroQol EQ-5D-5L
  • NYHA Functional Class
  • LVEF on echocardiography at 6 months and 1 year
  • Cardiovascular death, MI, CVA, major bleeding or unplanned revascularisation at 30 days
  • Hospitalisation for heart failure
  • Cardiovascular death
  • Acute myocardial infarction
  • Appropriate ICD therapy
  • Unplanned further revascularisation
  • Canadian Cardiovascular Society (CCS) class
  • NHS resource use
  • Brain natriuretic peptide (BNP or NT-Pro BNP) level
  • Major bleeding


Comments are closed.